Overcoming Solubility Limits: Crystal Polymorphism and Bioavailability Optimization
Formulation R&D Team•September 18, 2026•7 min read
Over 40% of newly developed chemical entities fall under BCS Class II, characterized by low aqueous solubility but high membrane permeability. Ensuring repeatable therapeutic delivery requires cutting-edge physical stabilization.
Our R&D laboratory utilizes X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) to characterize crystal forms during scale-up.
Through optimized solid dispersion carriers and fluidized-bed spray coating, Icon Drugs formulations achieve clinical absorption rates comparable to originator reference products, making vital therapies accessible to wider patient demographics.